MITO8
Liposomal doxorubicin stealth vs. carboplatin/paclitaxel in recurrent ovarian cancer patients with platinum-free interval between 6-12 months
MITO
MITO12
Pathway to diagnosis of ovarian cancer: an observational retrospective multicentred study
Trial Number
NCT01061619 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
MITO CERV 2
Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer (MITO CERV 2)
Trial Number
NCT00997009 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
MITO7
First line weekly carboplatin and paclitaxel versus every 3 weeks carboplatin/paclitaxel in patients with ovarian cancer: phase III multicentre trial
Trial Number
NCT00660842 (ClinicalTrials.gov ID)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
MITO23
Randomized phase III trial on Trabectedin (ET 743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients
Trial Number
NCT02903004 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
A18-00/ENGOT-CX11
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer